Bhowmik, Achol A. http://orcid.org/0000-0002-1491-5899
Heikkilä, Taina R. H.
Polari, Lauri http://orcid.org/0000-0002-0052-6489
Virta, Jenni http://orcid.org/0000-0003-1062-8187
Liljenbäck, Heidi http://orcid.org/0000-0001-9372-1584
Moisio, Olli http://orcid.org/0000-0002-2473-459X
Li, Xiang-Guo http://orcid.org/0000-0002-9118-7223
Viitanen, Riikka http://orcid.org/0000-0003-0937-356X
Jalkanen, Sirpa http://orcid.org/0000-0002-1922-9732
Koffert, Jukka http://orcid.org/0000-0003-3375-8961
Toivola, Diana M. http://orcid.org/0000-0001-7165-9839
Roivainen, Anne http://orcid.org/0000-0002-4006-7977
Funding for this research was provided by:
Terveyden Tutkimuksen Toimikunta (315139, 332582, 347251, 350117)
Sigrid Juséliuksen Säätiö
Jane ja Aatos Erkon Säätiö
Turun Yliopistollinen Keskussairaala (ERVA 13856)
Åbo Akademi
University of Turku
Article History
Received: 29 September 2023
Revised: 1 December 2023
Accepted: 4 December 2023
First Online: 18 December 2023
Declarations
:
: SJ owns stocks in Faron Pharmaceuticals. The remaining authors have no competing interests to disclose.
: All animal experiments were approved by the national Project Authorization Board in Finland (licenses ESAVI/16359/2019 and ESAVI/8648/2020) and were carried out in compliance with the ARRIVE guidelines. Human intestinal samples were from patients with UC participating in a clinical trial approved by the joint Ethics Committee of the University of Turku and Turku University Hospital (CLN9801, ethics approval 31.3.1998 §76, and amendment CLN9901 16.3.1999 §97).